Lesson plan

Uromune

Uromune, also known by its developmental code name MV-140, is a polyvalent bacterial vaccine which is used and is being developed for prevention of recurrent urinary tract infections (UTIs). In clinical studies, it has been found to reduce total number of UTIs by about 70%, to increase UTI-free rates from around 25% to 57%, and to increase time to next UTI from about 1.6 months to 9.0 months. It has also been found to reduce subjective UTI symptoms, reduce antibiotic use, and improve quality of life. The effectiveness of the vaccine appears to decrease with time, which might warrant readministration. Uromune is used as a sublingual spray once daily for 3 months. Side effects of Uromune are considered infrequent, minor, and usually not treatment-related. Uromune is an inactivated combination of four major bacteria known to cause recurrent UTIs, including Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus vulgaris. It is thought to work by increasing adaptive immunity against UTI-causing bacteria. It might also work by increasing trained immunity against these pathogens. Uromune first became available for clinical use in 2010 and was first described in the literature by 2012. It was developed and marketed in Spain by Immunotek S.L. Uromune has also been approved in Mexico and the Dominican Republic and is currently pending approval in Canada.…

Back to article

Article summary

Uromune, also known by its developmental code name MV-140, is a polyvalent bacterial vaccine which is used and is being developed for prevention of recurrent urinary tract infections (UTIs). In clinical studies, it has been found to reduce total number of UTIs by about 70%, to increase UTI-free rates from around 25% to 57%, and to increase time to next UTI from about 1.6 months to 9.0 months. It has also been found to reduce subjective UTI symptoms, reduce antibiotic use, and improve quality of life. The effectiveness of the vaccine appears to decrease with time, which might warrant readministration. Uromune is used as a sublingual spray once daily for 3 months. Side effects of Uromune are considered infrequent, minor, and usually not treatment-related. Uromune is an inactivated combination of four major bacteria known to cause recurrent UTIs, including Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus vulgaris. It is thought to work by increasing adaptive immunity against UTI-causing bacteria. It might also work by increasing trained immunity against these pathogens. Uromune first became available for clinical use in 2010 and was first described in the literature by 2012. It was developed and marketed in Spain by Immunotek S.L. Uromune has also been approved in Mexico and the Dominican Republic and is currently pending approval in Canada.…

Key claims

  1. publication date: 2021 — source: Wikipedia, revision 1344805930, retrieved 2026-10-20 · confidence 0.95

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. The record states that the publication date is "2021". What evidence would count against this claim?
  3. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  4. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

  1. Wikipedia, “Uromune”, revision 1344805930, retrieved 2026-10-20 https://en.wikipedia.org/w/index.php?oldid=1344805930

Key claims and bibliography are generated from the same tracked claims and sources as the article page.